



Aequus Collaborates with reVision to Pursue Stargardt Disease Program

August 18th, 2021

Northview LifeSciences is excited to announce that our portfolio partner Aequus Pharmaceuticals has finalized a collaboration plan with reVision Therapeutics to combat Stargardt disease. Stargardt disease is a rare genetic ocular disorder affecting the vision of children, often progressively resulting in legal blindness. Currently, there is no standard therapeutic option for this disease and tends to go untreated. This agreement will allow the pursuit of a possible therapeutic option to combat the effects of this genetic disease, hopefully preventing disease progression. With this collaboration in place, Northview is excited to see the next steps the two companies take in tackling the treatment of this orphan disease.

[Aequus Pharma Official Press Release](#)

Northview LifeSciences Advancing the Business of Science